Search research articles
Contact Us
Filters
Showing results (151-160 of 215) with videos related to
Page
of 22
Sort By:
The New England Journal of Medicine
|
June 13, 2019
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
Daniela Matei, Virginia Filiaci, Marcus E Randall, et al.
Gynecologic Oncology
|
March 9, 2025
Role of adjuvant radiotherapy modality on clinical outcomes for early-stage uterine carcinosarcoma
Kevin Tyan, Kevin X Liu, Alicia C Smart, et al.
Cell Reports
|
December 13, 2018
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
Liya Ding, Hye-Jung Kim, Qiwei Wang, et al.
Gynecologic Oncology
|
August 11, 2020
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial
Elizabeth K Lee, Niya Xiong, Su-Chun Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2022
Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers
Felipe Batalini, Doga C Gulhan, Victor Mao, et al.
Gynecologic Oncology
|
January 15, 2019
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial
Michel Fabbro, Kathleen N Moore, Anne Dørum, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 10, 2012
Cancer- and chemotherapy-induced anemia
George M Rodgers, Pamela Sue Becker, Morey Blinder, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 22, 2021
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy
Angelina Tjokrowidjaja, Michael Friedlander, Sarah J Lord, et al.
The Lancet. Oncology
|
September 15, 2014
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F Liu, William T Barry, Michael Birrer, et al.
Journal for Immunotherapy of Cancer
|
December 23, 2025
Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer
Rebecca Porter, Bruno Bockorny, Bradley R Corr, et al.
Page
of 22
Search research articles
Search
Showing results (151-160 of 215) with videos related to
Sort By:
Page
of 22
The New England Journal of Medicine
|
June 13, 2019
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
Daniela Matei, Virginia Filiaci, Marcus E Randall, et al.
Gynecologic Oncology
|
March 9, 2025
Role of adjuvant radiotherapy modality on clinical outcomes for early-stage uterine carcinosarcoma
Kevin Tyan, Kevin X Liu, Alicia C Smart, et al.
Cell Reports
|
December 13, 2018
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
Liya Ding, Hye-Jung Kim, Qiwei Wang, et al.
Gynecologic Oncology
|
August 11, 2020
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial
Elizabeth K Lee, Niya Xiong, Su-Chun Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2022
Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers
Felipe Batalini, Doga C Gulhan, Victor Mao, et al.
Gynecologic Oncology
|
January 15, 2019
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial
Michel Fabbro, Kathleen N Moore, Anne Dørum, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
May 10, 2012
Cancer- and chemotherapy-induced anemia
George M Rodgers, Pamela Sue Becker, Morey Blinder, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 22, 2021
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy
Angelina Tjokrowidjaja, Michael Friedlander, Sarah J Lord, et al.
The Lancet. Oncology
|
September 15, 2014
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F Liu, William T Barry, Michael Birrer, et al.
Journal for Immunotherapy of Cancer
|
December 23, 2025
Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer
Rebecca Porter, Bruno Bockorny, Bradley R Corr, et al.
Page
of 22